TEL AVIV UNIVERSITY

NeuroSense Therapeutics' PrimeC demonstrated a statistically significant 33% reduction in ALS disease progression (p=0.007) and 58% improvement in survival rates in its Phase 2b PARADIGM trial.

Israeli researchers have achieved a world-first breakthrough by developing an mRNA vaccine that provides complete protection against Yersinia pestis, the bacterium causing bubonic and pneumonic plague, in animal models.

Apex Labs received Israeli Ministry of Health approval to add two clinical trial sites for its SUMMIT-90 phase 2b study evaluating psilocybin for PTSD treatment.

Researchers from Tel Aviv University and Sheba Medical Center have developed a bioengineered skin graft using patients' own cells that heals burns in half the time of standard treatments.

Merck KGaA has become a strategic partner in Peregrine Ventures' Incentive Incubator, gaining early access to startups in bioconvergence, pharma, and biotechnology fields.

• Cytora's novel stem cell therapy hOMSC200, derived from human oral mucosa stem cells, demonstrated safety and efficacy in treating chronic diabetic foot ulcers with no immune rejection in a Phase 1/2a trial. • The treatment achieved 53% wound closure rate in the intent-to-treat population versus 33% with standard care, and remarkably showed 100% success in patients who adhered to protocol guidelines compared to 20% in the placebo group. • The company plans to apply for an IND in late 2025 to advance to a larger Phase 2 trial in 2026, targeting the significant unmet need in diabetic foot ulcers that affect up to 34% of diabetes patients.

Tel Aviv University researchers have successfully used CRISPR gene-editing technology to eliminate 50% of head and neck tumors in model animals by targeting the SOX2 gene, challenging previous assumptions about CRISPR's limitations in cancer therapy.

Tel Aviv University researchers have developed a groundbreaking method to deliver mRNA-based drugs directly to inflamed intestines while bypassing the liver, potentially revolutionizing IBD treatment.

Researchers at Tel Aviv University have discovered that NMDA receptors (NMDARs) play a crucial role in maintaining brain stability, or homeostasis, beyond their known function in learning and memory.

Israeli researchers from Tel Aviv University and the Israel Institute for Biological Research have developed the world's first mRNA vaccine effective against deadly bacteria, achieving 100% protection in animal studies.